An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

Cancer

Volumn 73, Issue 3, 1994, Pages 688-691

  Witte, Robert S ^a,d   Elson, Paul ^b   Khandakar, Janardan ^c   Trump, Donald L ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^d GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

antifol; bladder cancer; methotrexate; trimetrexate; urothelial neoplasms

Indexed keywords

CISPLATIN; METHOTREXATE; PLATINUM DERIVATIVE; TRIMETREXATE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARCINOMA; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UROGENITAL TRACT TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIMETREXATE;

EID: 0028174048     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19940201)73:3<688::AID-CNCR2820730330>3.0.CO;2-V     Document Type: Article

References (17)

1. Chemotherapy for advanced urothelial cancer
2. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse
3. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study
4. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group trial
5. Uptake and efficacy of trimetrexate (TMQ, 2,4‐diamino‐5‐methyl‐6‐[(3,4,5‐timethoxyanilino)methyl]quinazoline), a nonclassical antifolate, in methotrexate‐resistant leukemia cells in vitro
6. Preclinical studies with trimetrexate: a review of conclusions and unanswered questions
7. Biochemical and biological characterization of two new antifols, NSC 127755 and TMQ, in comparison with methotrexate [abstract]
8. Toxicity and response criteria of the Eastern Cooperative Oncology Group
9. Nonparametric estimation from incomplete observations
10. Chemotherapy of urothelial tract tumors
11. Randomized Phase II comparison of carboplatin and chip in advanced transitional cell carcinoma of the urothelium: the Eastern Cooperative Oncology Group
12. Trimetrexate: a Phase 2 study in previously treated patients with metastatic breast cancer
13. Trimetrexate in advanced carcinoma of the esophagus
14. Phase II trial of trimetrexate in patients with Stage III and IV non‐small‐cell lung cancer
15. Trimetrexate: predictors of severe or life‐threatening effects
16. Correlates of severe or life‐threatening toxic effects from trimetrexate
17. Trimetrexate combined with cisplatin or etoposide in the treatment of non‐small cell lung cancer: a pilot study